The PRODIGE 59-DURIGAST trial: A randomized phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-esophageal junction adenocarcinoma.

被引：0

作者：

Tougeron, David

Dahan, Laetitia

El Hajbi, Farid

Le Malicot, Karine

Evesque, Ludovic

Aparicio, Thomas

Bouche, Olivier

Bonichon-Lamichhane, Nathalie

Chibaudel, Benoist

Angelergues, Antoine

Bordere, Anais

Phelip, Jean-Marc

Mabro, May

Artru, Pascal

Louvet, Christophe

机构：

[1] Univ Poitiers Hosp, Gastroenterol Dept, Poitiers, France

[2] Univ Hosp Timone, Hepatogastroenterol & Oncol Dept, Marseille, France

[3] Ctr Oscar Lambret, Lille, France

[4] FFCD, Dijon, France

[5] INSERM, U1231, Dijon, France

[6] Ctr Antoine Lacassagne, Nice, France

[7] Hop St Louis, AP HP, Dept Gastroenterol, Paris, France

[8] Hop Robert Debr, Reims, France

[9] Clin Tivolis Ducos, Bordeaux, France

[10] Hosp Franco Britann, Fdn Cognacq Jay, Med Oncol, Levallois Perret, France

[11] Diaconesses Croix Simon Hosp, Paris, France

[12] St Malo Hosp, St Malo, France

[13] Univ Jean Monnet, St Etiennes, France

[14] Hop Foch, Suresnes, France

[15] Hop Prive Jean Mermoz, Lyon, France

[16] Inst Mutualiste Montsouris, Dept Med Oncol, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4036

引用

页数：1

共 50 条

[21] Phase II study of NUC-3373, leucovorin, irinotecan (NUFIRI) plus bevacizumab vs FOLFIRI plus bevacizumab for the second-line treatment of patients with advanced/metastatic colorectal cancer (NuTide:323)
Wilson, Richard H.
Ciombor, Kristen K.
Coveler, Andrew L.
Graham, Janet S.
Schlechter, Benjamin L.
George, Thomas J.
Elez, Elena
Evans, T. R. Jeffry
Berlin, Jordan
de Gramont, Aimery
McKissock, Fiona G.
Oelmann, Elisabeth
Bloss, Jeffrey D.
Martini, Giulia
Bennouna, Jaafar
Modest, Dominik P.
Taieb, Julien
Tabernero, Josep
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[22] Phase 2 study of azacitidine (AZA) plus pembrolizumab (pembro) as second-line treatment in patients with advanced pancreatic ductal adenocarcinoma.
Safyan, Rachael A.
Manji, Gulam Abbas
Lee, Shing Mirn
Silva, Rebecca
Bates, Susan Elaine
White, Ruth Aroon
Jamison, Jacob K. R.
Bass, Adam Joel
Schwartz, Gary K.
Oberstein, Paul Eliezer
Gonda, Tamas
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[23] A phase1b study of navicixizumab plus FOLFIRI in second-line treatment of patients with metastatic colorectal cancer.
Lim, Kian-Huat
Iglesia, Michael
Culm, Kerry
Koustenis, Andrew G.
Mockbee, Colleen M.
Mathew, Lynn
Fakih, Marwan
Garrido-Laguna, Ignacio
Krauss, John C.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 111 - 111
[24] Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
Qu, Jinglei
He, Xin
Luo, Ying
Yu, Ping
Chen, Ying
Liu, Jing
Wang, Xin
Wang, Chang
Liang, Tingting
Bai, Yuxian
Han, Yu
Man, Li
Leng, Chuanchun
Zhou, Caiyun
He, Lijie
Liu, Yunpeng
Qu, Xiujuan
FRONTIERS IN ONCOLOGY, 2023, 13
[25] Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma
Koutras, A. K.
Gerolymos, M. K.
Kontogeorgou, E.
Iconomou, G.
Vourli, G.
Tsiata, E.
Makatsoris, T.
Chrysanthopoulos, C.
Kalofonos, H. P.
JOURNAL OF CHEMOTHERAPY, 2007, 19 (06) : 724 - 730
[26] FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel- results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO
Lorenzen, Sylvie
Thuss-Patience, Peter
Pauligk, Claudia
Goekkurt, Eray
Ettrich, Thomas
Lordick, Florian
Stahl, Michael
Reichardt, Peter
Soekler, Martin
Pink, Daniel
Probst, Stefan
Hinke, Axel
Goetze, Thorsten O.
Al-Batran, Salah E.
EUROPEAN JOURNAL OF CANCER, 2022, 165 : 48 - 57
[27] Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): Preliminary results.
Pinto, C.
Di Fabio, F.
Siena, S.
Cascinu, S.
Llimpe, F. L. Rojas
Ceccarelli, C.
Mutri, V.
Giaquinta, S.
Piana, E.
Martoni, A. A.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 186S - 186S
[28] Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603)
Kawamoto, Yasuyuki
Yuki, Satoshi
Sawada, Kentaro
Nakamura, Michio
Muto, Osamu
Sogabe, Susumu
Shindo, Yoshiaki
Ishiguro, Atsushi
Sato, Atsushi
Tsuji, Yasushi
Dazai, Masayoshi
Okuda, Hiroyuki
Sasaki, Takahide
Harada, Kazuaki
Nakano, Shintaro
Nakatsumi, Hiroshi
Sekiguchi, Mari
Sakata, Yuh
Sakamoto, Naoya
Komatsu, Yoshito
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[29] A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer
Ranhua Cao
Shuai Zhang
Dedong Ma
Likuan Hu
Medical Oncology, 2015, 32
[30] Phase II study of FOLFIRI with low-dose irinotecan plus ramucirumab as second-line treatment in Japanese patients with metastatic colorectal cancer (RINDO study).
Hattori, Masashi
Hattori, Norifumi
Nakayama, Goro
Umeda, Shinichi
Kishida, Takayoshi
Kawase, Yoshihisa
Ezaka, Kazuhiro
Tsutsuyama, Masayuki
Sakai, Mitsuru
Ito, Takeshi
Yanbe, Yutaka
Kanda, Mitsuro
Tanaka, Chie
Murotani, Kenta
Ando, Masahiko
Kodera, Yasuhiro
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 124 - 124

← 1 2 3 4 5 →